Virus-like antigen display for cancer vaccine development, what is the potential?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Virus-like antigen display for cancer vaccine development, what is the potential?
Authors
Keywords
-
Journal
Expert Review of Vaccines
Volume 17, Issue 4, Pages 285-288
Publisher
Informa UK Limited
Online
2018-03-21
DOI
10.1080/14760584.2018.1455505
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies
- (2018) Aimée R. Kreimer et al. VACCINE
- Virus-like particle display of HER2 induces potent anti-cancer responses
- (2018) Arianna Palladini et al. OncoImmunology
- Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response
- (2017) Atefeh Arab et al. IMMUNOLOGIC RESEARCH
- Virus like particles as a platform for cancer vaccine development
- (2017) Hui Kian Ong et al. PeerJ
- A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer
- (2016) Giuseppe Curigliano et al. BREAST CANCER RESEARCH AND TREATMENT
- Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
- (2016) N. J. Mason et al. CLINICAL CANCER RESEARCH
- Bacterial superglue enables easy development of efficient virus-like particle based vaccines
- (2016) Susan Thrane et al. JOURNAL OF NANOBIOTECHNOLOGY
- Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform
- (2016) Josef Singer et al. OncoImmunology
- Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity
- (2015) Jaina M. Patel et al. BIOTECHNOLOGY AND BIOENGINEERING
- Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
- (2014) A. Makkouk et al. CANCER RESEARCH
- Hypersensitivity Reactions to Biologic Agents
- (2014) Alessandra Vultaggio et al. IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
- Active immunotherapy for chronic diseases
- (2013) Martin F. Bachmann et al. VACCINE
- A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin
- (2012) B. Zakeri et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles
- (2011) Seyed Amir Jalali et al. Nanomedicine-Nanotechnology Biology and Medicine
- In silico Modeling and In vivo Efficacy of Cancer-Preventive Vaccinations
- (2010) A. Palladini et al. CANCER RESEARCH
- A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study
- (2009) Ursula Wiedermann et al. BREAST CANCER RESEARCH AND TREATMENT
- Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
- (2008) G. E. Peoples et al. CLINICAL CANCER RESEARCH
- Murine pneumotropic virus chimeric Her2/neuvirus-like particles as prophylactic and therapeutic vaccines against Her2/neuexpressing tumors
- (2008) Kalle Andreasson et al. INTERNATIONAL JOURNAL OF CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started